{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:57:15Z","timestamp":1768517835997,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:00:00Z","timestamp":1794096000000},"content-version":"am","delay-in-days":707,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028726","name":"Oklahoma Restaurant Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021216","name":"Office of Regulatory Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021216","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography A"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.chroma.2024.465488","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T10:00:56Z","timestamp":1730628056000},"page":"465488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Evaluation of size-based distribution of components in VYXEOS\u00ae liposomal formulation using asymmetric flow field-flow fractionation"],"prefix":"10.1016","volume":"1738","author":[{"given":"Dumindika A.","family":"Siriwardane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheyda","family":"Shakiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thilak","family":"Mudalige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.chroma.2024.465488_bib0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nnano.2017.67","article-title":"The evolving landscape of drug products containing nanomaterials in the United States","volume":"12","author":"D'Mello","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.chroma.2024.465488_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/IJN.S288236","article-title":"Engineered nanomaterials: the challenges and opportunities for nanomedicines","volume":"16","author":"Albalawi","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.chroma.2024.465488_bib0003","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nbt1006-1211","article-title":"The emerging nanomedicine landscape","volume":"24","author":"Wagner","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chroma.2024.465488_bib0004","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/pharmaceutics10030151","article-title":"Development of dual drug loaded nanosized liposomal formulation by a reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies","volume":"10","author":"Sarfraz","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.chroma.2024.465488_bib0005","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/13543776.2019.1679767","article-title":"An update on liposomes in drug delivery: a patent review (2014-2018)","volume":"29","author":"El-Hammadi","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.chroma.2024.465488_bib0006","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.chroma.2024.465488_bib0007","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.chroma.2024.465488_bib0008","doi-asserted-by":"crossref","first-page":"038","DOI":"10.4103\/2278-330X.149950","article-title":"Novel formulation of cytarabine and daunorubicin: a new hope in AML treatment","volume":"4","author":"Raut","year":"2015","journal-title":"South Asian J. Cancer"},{"key":"10.1016\/j.chroma.2024.465488_bib0009","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chroma.2024.465488_bib0010","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","article-title":"Daunorubicin\/cytarabine liposome: a review in acute myeloid leukaemia","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.chroma.2024.465488_bib0011","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","article-title":"CPX-351 (vyxeos) in AML","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.chroma.2024.465488_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mpo.2950100707","article-title":"Biochemical pharmacology of cytosine arabinoside","volume":"10","author":"Momparler","year":"1982","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.chroma.2024.465488_bib0013","series-title":"Mechanism of Action of Antimicrobial and Antitumor Agents","first-page":"101","article-title":"Daunomycin (Daunorubicin) and adriamycin and structural analogues: biological activity and mechanism of action","author":"Di Marco","year":"1975"},{"key":"10.1016\/j.chroma.2024.465488_bib0014","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.02.014","article-title":"Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin","volume":"391","author":"Dicko","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0015","unstructured":"US Food and Drug Administration, Liposome drug products chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation, Guidance for Industry, (2018)."},{"key":"10.1016\/j.chroma.2024.465488_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118603","article-title":"Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation","volume":"569","author":"Van Haute","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0022-3565(25)21638-X","article-title":"Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats","volume":"226","author":"Allen","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.chroma.2024.465488_bib0018","first-page":"12","article-title":"Liposomes as a novel drug delivery system: fundamental and pharmaceutical application","author":"Salimi","year":"2018","journal-title":"Asian J. Pharm. (AJP)"},{"key":"10.1016\/j.chroma.2024.465488_bib0019","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.colsurfb.2017.11.033","article-title":"Liposomally formulated phospholipid-conjugated novel near-infrared fluorescence probe for particle size effect on cellular uptake and biodistribution in vivo","volume":"161","author":"Xing","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.chroma.2024.465488_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0169-409X(99)00041-1","article-title":"The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs","volume":"40","author":"Nagayasu","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.chroma.2024.465488_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118906","article-title":"Characterization of doxorubicin liposomal formulations for size-based distribution of drug and excipients using asymmetric-flow field-flow fractionation (AF4) and liquid chromatography-mass spectrometry (LC-MS)","volume":"574","author":"Ansar","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2019.103982","article-title":"Quality by design based development and validation of HPLC method for simultaneous estimation of paclitaxel and vinorelbine tartrate in dual drug loaded liposomes","volume":"149","author":"Bonde","year":"2019","journal-title":"Microchem. J."},{"key":"10.1016\/j.chroma.2024.465488_bib0023","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2020.04.018","article-title":"Design principles of drug combinations for chemotherapy","volume":"323","author":"Wu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chroma.2024.465488_bib0024","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jconrel.2020.01.049","article-title":"Physical characterization of liposomal drug formulations using multi-detector asymmetrical-flow field flow fractionation","volume":"320","author":"Parot","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chroma.2024.465488_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2019.02.030","article-title":"Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity","volume":"299","author":"Caputo","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chroma.2024.465488_bib0026","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/nnm-2017-0338","article-title":"Are existing standard methods suitable for the evaluation of nanomedicines: some case studies","volume":"13","author":"Gioria","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.chroma.2024.465488_bib0027","series-title":"Light Scattering, Size Exclusion Chromatography and Asymmetric Flow Field Flow Fractionation: Powerful Tools for the Characterization of Polymers, Proteins and Nanoparticles","author":"Podzimek","year":"2011"},{"key":"10.1016\/j.chroma.2024.465488_bib0028","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/acs.molpharmaceut.8b01033","article-title":"Measuring particle size distribution by asymmetric flow field flow fractionation: a powerful method for the preclinical characterization of lipid-based nanoparticles","volume":"16","author":"Caputo","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461767","volume":"1635","author":"Caputo","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2024.465488_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.113017","article-title":"Advanced nanomedicine characterization by DLS and AF4-UV-MALS: application to a HIV nanovaccine","volume":"179","author":"Klein","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2024.465488_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jpba.2016.02.037","article-title":"The use of asymmetrical flow field-flow fractionation with on-line detection in the study of drug retention within liposomal nanocarriers and drug transfer kinetics","volume":"124","author":"Hinna","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2024.465488_bib0032","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2016.06.057","article-title":"Docetaxel-loaded liposomes: the effect of lipid composition and purification on drug encapsulation and in vitro toxicity","volume":"514","author":"Pereira","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0033","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/08982100802129372","article-title":"Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations","volume":"18","author":"Johnston","year":"2008","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.chroma.2024.465488_bib0034","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0378-5173(92)90015-T","article-title":"Drug encapsulation and release from multilamellar and unilamellar liposomes","volume":"81","author":"Betageri","year":"1992","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0035","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/biom8040174","article-title":"Quantification of lipids: model, reality, and compromise","volume":"8","author":"Khoury","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.chroma.2024.465488_bib0036","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mas.21492","article-title":"Selection of internal standards for accurate quantification of complex lipid species in biological extracts by electrospray ionization mass spectrometry\u2013what, how and why?","volume":"36","author":"Wang","year":"2017","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.chroma.2024.465488_bib0037","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2010.08.026","article-title":"Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge","volume":"148","author":"Dadashzadeh","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chroma.2024.465488_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.chroma.2024.465488_bib0039","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","article-title":"Influence of cholesterol on liposome stability and on in vitro drug release","volume":"5","author":"Briuglia","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.chroma.2024.465488_bib0040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.09.047","article-title":"A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: from liposomal preparation to therapy","volume":"551","author":"Farzaneh","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0041","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1021\/mp100245u","article-title":"Copper\u2212doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity","volume":"7","author":"Kheirolomoom","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0042","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/molecules22071106","article-title":"Newly synthesized doxorubicin complexes with selected metals\u2013synthesis, structure and anti-breast cancer activity","volume":"22","author":"Jab\u0142o\u0144ska-Trypu\u0107","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.chroma.2024.465488_bib0043","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2006.05.019","article-title":"Copper\u2013topotecan complexation mediates drug accumulation into liposomes","volume":"114","author":"Taggar","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chroma.2024.465488_bib0044","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejps.2008.05.006","article-title":"Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release","volume":"34","author":"Li","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.chroma.2024.465488_bib0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2007.01.004","article-title":"Role of copper gluconate\/triethanolamine in irinotecan encapsulation inside the liposomes","volume":"337","author":"Dicko","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.chroma.2024.465488_bib0046","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1208\/s12249-020-01867-x","article-title":"Contrastive studies of cytarabine\/daunorubicin dual-loaded liposomes prepared by pH gradient and Cu2+ gradient method","volume":"21","author":"Zhang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.chroma.2024.465488_bib0047","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1021\/la404434q","article-title":"Origins of microstructural transformations in charged vesicle suspensions: the crowding hypothesis","volume":"30","author":"Seth","year":"2014","journal-title":"Langmuir"},{"key":"10.1016\/j.chroma.2024.465488_bib0048","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0006-3495(91)82117-8","article-title":"Shape transitions and shape stability of giant phospholipid vesicles in pure water induced by area-to-volume changes","volume":"60","author":"K\u00e4s","year":"1991","journal-title":"Biophys. J."}],"container-title":["Journal of Chromatography A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967324008628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967324008628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:03:06Z","timestamp":1762192986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021967324008628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":48,"alternative-id":["S0021967324008628"],"URL":"https:\/\/doi.org\/10.1016\/j.chroma.2024.465488","relation":{},"ISSN":["0021-9673"],"issn-type":[{"value":"0021-9673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of size-based distribution of components in VYXEOS\u00ae liposomal formulation using asymmetric flow field-flow fractionation","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography A","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chroma.2024.465488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"465488"}}